Author + information
- Kristopher Swiger,
- Eric Farber-Eger,
- Benjamin Holmes,
- Jeffrey Carr,
- Kim Sandler,
- Daniel Munoz and
- Freiberg Matthew
Background: Patients eligible for lung cancer screening (LCS) have an increased risk of cardiovascular disease (CVD). Coronary artery calcium (CAC) scoring is incidentally obtained during LCS. Whether CAC reporting affects statin prescribing is unclear. We assessed CAC prevalence, statin prescribing, and CVD event rates among LCS participants.
Methods: LSC participants were identified via the Vanderbilt Synthetic Derivative, a de-identified clinical database of 2.5 million patients. CAC scores were estimated using a modified Agatston method and reported as quartiles (none, mild [estimated score 1-100], moderate [101-400], severe [>400]). Statin prescription status and CVD event data were ascertained via clinical documentation.
Results: Among 426 LCS participants, 86% had CAC (Table). Nearly half (42%) were not taking statins prior to LCS. Among 127 participants not on statin therapy at the time of LCS, with an ASCVD score ≥7.5%, and with CAC reported on LCS, only 6% received statin therapy within 3 months post-LCS. Within one year post-LCS, there were 101 CVD events with a mortality rate of 10% (Table).
Conclusions:LCS participants have a high prevalence of CAC, nearly half are not on statin therapy, and few begin statins following CAC results. For high-risk LCS participants with severe CAC and not on statins, rates of CVD and death are high. Future studies should evaluate LCS as tool for identifying and stratifying participants at high risk for CVD events.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Current Issues in Cardiovascular Epidemiology, Disparities, and Safety
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1148-066
- 2017 American College of Cardiology Foundation